CN108853141A - Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation - Google Patents
Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation Download PDFInfo
- Publication number
- CN108853141A CN108853141A CN201710322487.9A CN201710322487A CN108853141A CN 108853141 A CN108853141 A CN 108853141A CN 201710322487 A CN201710322487 A CN 201710322487A CN 108853141 A CN108853141 A CN 108853141A
- Authority
- CN
- China
- Prior art keywords
- oil
- fullerene
- soluble
- bulk material
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Abstract
The invention discloses a kind of application of oil-soluble fullerene structure in the drug that preparation inhibits tumour growth, wherein the oil-soluble fullerene structure includes at least one of following effective component：Oil-soluble fullerene, oil soluble metal fullerene, the oil-soluble fullerene and the oil soluble metal fullerene composition, the pharmaceutical ester of the above three or the pharmaceutical salt of the above three.Oil-soluble fullerene structure of the present invention has good compatibility with organism, toxicity is low, high-efficient to the inhibition of tumour compared with clinical cyclophosphamide, taxol generally used etc. at present；And the empty fullerene nano material cost in the present invention is more cheap, it can popularity application.
Description
Technical field
The present invention relates to biomedicine field, in particular to a kind of oil-soluble fullerene structure inhibits tumour growth in preparation
Drug in application.
Background technique
Malignant tumour has obtained people's common concern as the major disease that 21 century influences human life and health.It is international
What Agency for Research on Cancer was published in 2013《The report of world's cancer》In point out, according to the incidence trend of current cancer, the year two thousand twenty
Whole world cancer morbidity will increase by 50% than now, and newly-increased cancer patient's number is up to 15,000,000 people every year in the whole world.In mesh
During pre-neoplastic is treated, chemotherapy is one of most common means, but chemotherapeutics lacks targeting, and killing, tumour is thin
Also it can cause the death of normal cell while born of the same parents, therefore can usually cause serious side effect.Not with antitumor research
, also there is a collection of anticancer new treatment, such as targeted therapy, immunotherapy, thermotherapy, photodynamic therapy etc. in disconnected development.
The caged Spectra of Carbon Clusters that fullerene is made of different number of carbon atoms is except graphite, diamond and unformed
Another allotrope of carbon except carbon.The most fullerene molecule of content is C60, followed by C70、C84, followed by contain
Measure relatively small number of C76、C78、C82Deng.Carbon cage inside additionally, due to fullerene is cavity structure, therefore its internal cavities can be interior
Embedding not homoatomic, ion or cluster are referred to as embedded fullerene, such as Gd C82, indicate that Gd is embedded in C82Cage structure
In ,@indicates at, and vivid expresses embedded meaning.Fullerene structure is because its unique molecular structure determines its uniqueness
Physicochemical properties.
The information disclosed in the background technology section is intended only to increase the understanding to general background of the invention, without answering
When being considered as recognizing or imply that the information constitutes the prior art already known to those of ordinary skill in the art in any form.
Summary of the invention
It is an object of the present invention to provide a kind of oil-soluble fullerene structures in the drug that preparation inhibits tumour growth
Application.It is a further object of the present invention to provide a kind of medicine groups for inhibiting tumour growth using above-mentioned oil-soluble fullerene structure
Close object and method.
To achieve the goals above, the present invention provides following technical schemes：
The application of a kind of oil-soluble fullerene structure in the drug that preparation inhibits tumour growth, wherein the oil-soluble is rich
Strangling alkene structure includes at least one of following effective component：Oil-soluble fullerene, oil soluble metal fullerene, the oil-soluble
The composition of fullerene and the oil soluble metal fullerene, the pharmaceutical ester of the above three or the above three it is pharmaceutical
Salt.
The present invention also provides a kind of methods for inhibiting tumour growth, including to needing to inhibit the subject of tumour growth to apply
With a effective amount of oil-soluble fullerene structure, the oil-soluble fullerene structure includes at least one of following effective component：
Oil-soluble fullerene, oil soluble metal fullerene, the oil-soluble fullerene and the oil soluble metal fullerene composition,
The pharmaceutical ester of the above three or the pharmaceutical salt of the above three.
The present invention also provides a kind of pharmaceutical compositions for inhibiting tumour growth, including oil-soluble fullerene structure, also wrap
Include at least one of pharmaceutical carrier, pharmaceutical diluent and pharmaceutical excipient, the oil-soluble fullerene knot
Structure includes at least one of following effective component：Oil-soluble fullerene, oil soluble metal fullerene, the oil-soluble fullerene
With the pharmaceutical salt of the composition of the oil soluble metal fullerene, the pharmaceutical ester of the above three or the above three.
In another embodiment, the oil-soluble fullerene is by fullerene for above-mentioned application, method or pharmaceutical composition
Bulk material is obtained through oil-soluble modification；The oil soluble metal fullerene is modified through oil-soluble by metal fullerene bulk material
It obtains.
In another embodiment, the fullerene bulk material includes one for above-mentioned application, method or pharmaceutical composition
Kind or a variety of general formulas are C2mThe cage structure being made of carbon atom, 30≤m≤60, such as；C60, C70, C84Deng.
Above-mentioned application, method or pharmaceutical composition in another embodiment, the metal fullerene bulk material packet
Include M@C2n、M2@C2n、MA@C2n、M3N@C2n、M2C2@C2n、M2S@C2n、M2O@C2nAnd MxA3-xN@C2nOne of or it is a variety of,
In：M, A represents metallic element and M, A are selected from any one in lanthanide element, Sc and Y, 30≤n≤60；0≤x
≤3.N represents nitrogen, and C represents carbon, and S represents element sulphur, lanthanide element include La, Ce, Pr, Nd, Pm, Sm, Eu,
Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
Above-mentioned application, method or pharmaceutical composition in another embodiment, the modified effective way of the oil-soluble
It is fullerene bulk material and/or metal fullerene bulk material is modified through oil-soluble by covalently or non-covalently acting on
It arrives.Specific modified (modification the is referred to as modifying) method of oil-soluble can be carried out according to method disclosed in the prior art, such as：
Coat the fullerene bulk material with edible oil and/or metal fullerene bulk material obtain the oil-soluble fullerene and/
Or oil soluble metal fullerene, the mode specifically coated can be used fullerene bulk material and/or metal fullerene ontology material
Material is scattered in the edible oil, obtains mixed liquor, by gained mixed liquor successively through centrifugation removal precipitating, then by gained upper layer
Liquid filters to get oil-soluble modification liquid；It optionally, further include the processing of ball milling or ultrasound before the mixed liquor centrifugation.
Above-mentioned application, method or pharmaceutical composition in another embodiment, will during the oil-soluble is modified
Every 0.05-500mg fullerene bulk material and/or metal fullerene bulk material are dispersed in every 1ml edible oil, the range
The open disclosure that should be considered to be all numerical value in range, optionally has 0.05-1mg, 0.05-10mg, 0.05-100mg
Equal fullerenes bulk material and/or metal fullerene bulk material are dispersed in every 1ml edible oil.
Above-mentioned application, method or pharmaceutical composition in another embodiment, by the mixed liquor through ball milling or ultrasound
30min-15h。
In another embodiment, the centrifugation is passed through in the mixed liquor for above-mentioned application, method or pharmaceutical composition
After ball milling or ultrasound, the mixed liquor is placed in shady and cool drying and is kept in dark place, stands the regular hour, then carry out centrifugally operated.
Optionally, the regular hour refers to 2h-24h.
In another embodiment, the edible oil can be one-component for above-mentioned application, method or pharmaceutical composition
Oil, or the miscellas that different oil are formed.Optionally, edible oil is vegetable oil, such as olive oil, linseed oil, sunflower
Seed oil, maize germ, corn oil, palm oil, at least one of castor oil and soybean oil are also optionally animal fat, such as
Saualane etc..These oil have good biocompatibility, coat fullerene bulk material/metal fullerene bulk material with it
Prepare it is simple and quick, to living body without apparent toxic side effect.
In another embodiment, the oil-soluble fullerene is fullerene for above-mentioned application, method or pharmaceutical composition
The carbon cage outer surface of bulk material is coated with the modified fullerenes of oil solution, such as：The carbon cage outer surface of fullerene bulk material
The modified fullerenes of olive oil are coated with, the carbon cage outer surface of fullerene bulk material is coated with the modification fowler of sunflower oil
Alkene, the carbon cage outer surface of fullerene bulk material are coated with the modified fullerenes of linseed oil, the carbon cage of fullerene bulk material
Outer surface is coated with the modified fullerenes of saualane, and there are many what oil was formed to mix for the carbon cage outer surface cladding of fullerene bulk material
Close the modified fullerenes of oil.
In another embodiment, the oil soluble metal fullerene is gold for above-mentioned application, method or pharmaceutical composition
The carbon cage outer surface for belonging to fullerene bulk material is coated with the modified metal fullerene of oil solution, such as：Metal fullerene ontology
The carbon cage outer surface of material is coated with the modified metal fullerene of olive oil, the carbon cage appearance bread of metal fullerene bulk material
It is covered with the modified metal fullerene of sunflower oil, the carbon cage outer surface of metal fullerene bulk material is coated with changing for linseed oil
Property metal fullerene, the carbon cage outer surface of metal fullerene bulk material are coated with the modified metal fullerene of saualane, metal
The modified metal fullerene for the miscella that the carbon cage outer surface cladding of fullerene bulk material is formed there are many oil.
In another embodiment, the oil-soluble fullerene specifically includes for above-mentioned application, method or pharmaceutical composition
The C of edible oil cladding60, edible oil cladding C70Or the C of edible oil cladding84At least one of；The oil soluble metal fowler
Alkene specifically includes the Gd@C of edible oil cladding82。
In another embodiment, the oil-soluble fullerene and/or oil are molten for above-mentioned application, method or pharmaceutical composition
Property metal fullerene in, the concentration of the fullerene bulk material and/or metal fullerene bulk material can for 50~
50000ppm (mg/kg), such as 1500ppm.
In another embodiment, the inhibition tumour growth shows as preventing for above-mentioned application, method or pharmaceutical composition
Only or slow down the growth of tumour, optionally includes：Inhibit gross tumor volume to increase, tumor quality is inhibited to increase, slow down gross tumor volume
The speed of increase, the speed for slowing down tumor quality increase.
In another embodiment, the inhibition tumour growth is shown as not for above-mentioned application, method or pharmaceutical composition
Rely on the inhibition tumour growth of ray.
In another embodiment, the tumour includes liver cancer, lung cancer, knot for above-mentioned application, method or pharmaceutical composition
The intestines carcinoma of the rectum, kidney, cancer of pancreas, osteocarcinoma, breast cancer, oophoroma, prostate cancer, the cancer of the esophagus, gastric cancer, carcinoma of mouth, rhinocarcinoma, larynx
At least one of cancer, cholangiocarcinoma, cervical carcinoma, uterine cancer, carcinoma of testis, meningioma, cutaneum carcinoma, melanoma and sarcoma.
Drug or aforementioned pharmaceutical compositions in above-mentioned application in another embodiment, the drug or pharmaceutical composition
It is molten to can be tablet, pill, powder, pastille, sachet, cachet, elixir, suspending agent, emulsion, solution, syrup, gas
Glue, ointment, soft hard gelatin capsule, suppository, aseptic injectable solution or aseptic packaging powder-injection preparation.It will be effective in the present invention
Ingredient is prepared into drug or method known to a person of ordinary skill in the art can be used to prepare in the method for pharmaceutical composition, makes it
Quick-release, sustained release or sustained release effective component after being applied to subject, such as：Effective component can be mixed with carrier, with load
Body dilution or encapsulating are in the carrier.
Drug or aforementioned pharmaceutical compositions in above-mentioned application in another embodiment, the drug or pharmaceutical composition
When for liquid, concentration of the effective component in drug or pharmaceutical composition is 0.01-50mg/mL, and the disclosure of the range should be by
It is considered as the disclosure of all numerical value in range, optionally there is 0.01-10mg/mL, 10-20mg/mL, 20-30mg/mL, 30-
40mg/mL etc.；When the drug or pharmaceutical composition are solid, concentration of the effective component in drug or pharmaceutical composition is
0.01-50mg/g, the disclosure of the range should be considered to be the disclosure of all numerical value in range, optionally there is 0.01-10mg/g,
10-20mg/g, 20-30mg/g, 30-40mg/g etc.
Drug or aforementioned pharmaceutical compositions in above-mentioned application are suitable for as carrier, figuration in another embodiment
Some examples of agent and diluent include lactose, dextrose, sucrose, sorbierite, mannitol, starch, resin, Arabic gum, phosphorus
Sour calcium, alginate, tragacanth, gelatin, calcium silicates, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, aqueous syrup
(water syrup), methylcellulose, methylparaben and propyl ester, talcum powder, magnesium stearate and liquid paraffin.
Drug or aforementioned pharmaceutical compositions in above-mentioned application in another embodiment, the drug or pharmaceutical composition
The auxiliary agents such as lubricant, wetting agent, emulsification and suspending agent, preservative, sweetener or corrigent can also be also comprised.
In another embodiment, described subject is a human or animal for the above method, and animal can be mammal, such as
Mouse, cavy, rat, dog, rabbit, pig, monkey etc..
The above method in another embodiment, apply by the oil-soluble fullerene and/or oil soluble metal fullerene
It is 1mg/kg/d~100mg/kg/d with dosage, the dosage of specific subject is by weight of its weight carries out；The oil is molten
The application course for the treatment of of property fullerene and/or oil soluble metal fullerene is depending on the growth cycle of tumour, the growth of different tumours
Speed is different, can apply a couple of days to dozens of days etc.；The mode of the application can be stomach-filling or intraperitoneal injection, medicament used
Small, good absorbing is measured, curative effect is high；The opportunity of the application can be tumour growth initial stage, mid-term, latter stage, then optionally, application when
Machine is tumour growth initial stage.
Term used herein " effective component ", " effective component oil-soluble fullerene structure " or " oil-soluble fullerene
It is rich that structure " refers to oil-soluble fullerene, oil soluble metal fullerene, the oil-soluble fullerene and the oil soluble metal
Strangle at least one of composition, the corresponding pharmaceutical ester of the above three pharmaceutical salt corresponding with the above three of alkene.
Term used herein " effective quantity " refer to effective component through it is single or multiple be applied to patient and to diagnosing or
The patient treated provides the amount or dosage of intended effect.Effective quantity can be by the diagnostician that is participated in as those skilled in the art
By known technology and under similar situation, resulting observation result determines member.Determining the effective of applied effective component
When amount or dosage, the diagnostician participated in is considered as many factors, and the factor includes but is not limited to：The kind of mammal
Belong to；Volume, age and general health；Related disease specific；The disease involves in degree or severity；Individual patient
Response；The particular compound applied；Mode of administration；The bioavailability characteristics of applied preparation；Selected dosage regimen；
The use of concomitant drugs therapy；And other relevant situations.
Term used herein " fullerene bulk material " refers to that no fullerene modified, i.e. fullerene are former
Material.
Term used herein " metal fullerene bulk material " refers to no metal fullerene modified, i.e., golden
Belong to fullerene raw material.
It is the concrete content of all about oil-soluble fullerene and/or metal fullerene in the present invention, dense in order to facilitate metering
The quantitative restrictions such as degree are concrete content, the concentration with its corresponding fullerene bulk material or metal fullerene bulk material
Etc. measuring, such as：Concentration of the effective component in drug or pharmaceutical composition refers to detectable for 0.01-50mg/mL
Fullerene bulk material and/or concentration of the carbon cage in drug or pharmaceutical composition of metal fullerene bulk material be
0.01-50mg/mL.Wherein：Fullerene and metal fullerene can by inductive coupling plasma emission spectrograph (ICP) or
Person's liquid chromatograph HPLC is quantitative determined.
The disclosure of all ranges should be considered as the disclosure to subranges and all point values all in range in the present invention.Example
Such as：The disclosure of 1-1000 should be considered as also disclosing 1-200, the ranges such as 200-300, at the same also disclose 200,300,400,
500, the point values such as 600,700,800,900 and 100.
This field is developing cognitive domain, and the interpretation of claims hereof is not necessarily by any in the application
The limitation of specific theoretical or mechanism or deduction.
Compared with prior art, the present invention has the advantages that：
Oil-soluble fullerene structure of the present invention has following all properties：(1) fullerene bulk material and/or metal are rich
It strangles alkene bulk material and is eaten oily cladding, make it have fat-soluble characteristic, to be easier to enter cell, and can be via filling
Tumour and internal organs are reached in stomach or intraperitoneal injection to organism and by blood circulation；(2) it is kept in the material that cladding obtains
The integrality of carbon cage, the inhibition tumour growth characteristic with ontology.
Compared with oil-soluble fullerene structure of the present invention and current clinical cyclophosphamide, taxol generally used etc., with
Organism has good compatibility, and toxicity is low, high-efficient to the inhibition of tumour；And the empty fullerene nano material in the present invention
Cost is more cheap, can popularity application.
Detailed description of the invention
Fig. 1 is the tumor volume growth curve of separate groups of mice in the embodiment of the present invention 2.
Fig. 2 is the changes of weight curve of separate groups of mice in the embodiment of the present invention 2.
Specific embodiment
With reference to the accompanying drawing, specific embodiments of the present invention will be described in detail, it is to be understood that guarantor of the invention
Shield range is not limited by the specific implementation.
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
The preparation of embodiment 1, oil-soluble fullerene structure
1) by fullerene bulk material and/or metal fullerene bulk material, (purchase has in Xiamen good fortune material science and technology of taking in the fresh
Limit company, 99% or more purity) and olive oil, at least one of edible oils such as linseed oil mix in varing proportions, in ball
Ball milling 6-10h in grinding machine.
2) centrifuge is used after reacting, with revolving speed 10000r be centrifuged repeatedly away uncoated fullerene bulk material and/
Or metal fullerene bulk material, until no solid powder is centrifuged.
3) the fullerene bulk material/metal fullerene bulk material entered using ultraviolet-visible spectrometer test cladding
Specific concentration.
Oil-C60Preparation
100mg empty fullerene C60Solid powder and 100ml soybean oil mixing and ball milling 10h use centrifuge after reaction, use
Revolving speed 10000r is centrifuged repeatedly away uncoated C60Solid powder, until no solid powder is centrifuged, the soybean of preparation
In oil cladding empty fullerene, the concentration of empty fullerene is 1500ppm (mg/kg).
Embodiment 2, Oil-C60To the growth inhibition effect of source of people breast cancer MDA-MB-231
Animal strains：Balb/c Female nude mice, 5 weeks, weight was between 16-20g.
Tumor model：Source of people breast cancer MDA-MB-231 cell.
Administration mode：Stomach-filling
Experimental group：1, saline control group (Saline)；2, soybean oil control group (Oil)；3, positive drug (Japanese yew
Alcohol, paclitaxel) control group；4, experimental group (Oil-C60, 1500ppm).Every group 6 parallel.
Experimental method：100 μ L concentration of each group mouse hypodermic inoculation is 5 × 107The source of people breast cancer MDA-MB-231 of/ml is thin
Born of the same parents.Inoculation starts to be administered for 24 hours afterwards, and each group of dosage is as follows：Saline control group gives 200 μ L physiological saline daily；
Soybean oil control group gives 200 μ L soybean oils daily；Positive drug control group was administered once every 3 days, and the dosage being administered every time is
10mg/kg；The Oil-C of the preparation of embodiment 1 is given once daily in experimental group60, the dosage of daily administration is the Oil-C of 1500ppm60
200 μ L (about 15mg/kg/d) were tested to end in the 21st day.Mouse weight is every other day weighed during experiment and observes tumour
Growing state, observation ends in 21 days to after being inoculated with are tested, and take mouse tumor to weigh and measure volume, while taking internal organ is with 4%
Paraformaldehyde fixer is fixed.
Experimental result：As shown in Figure 1, positive drug control group and Oil-C60The gross tumor volume of group is significantly less than physiological saline
Control group and soybean oil control group, and the gross tumor volume of soybean oil control group is not significantly different with saline control group, is said
Bright individual finish (soybean oil) does not influence the growth of tumour.And give Oil-C60Obviously slow down the growth of tumour afterwards,
(such as following table), positive drug control group and Oil-C in terms of tumor weight at the end of the experiment60The tumor weight of group is also significantly less than life
Saline control group and soybean oil group are managed, demonstrates Oil-C again60It can inhibit the growth of tumour.
From Fig. 2, it can be seen that, by comparing the changes of weight of separate groups of mice, the mouse weight of positive control medicine group is compared
It is more obvious in other three groups of declines, and when administration time persistently lengthens, continued weight decline embodies positive control drug
Side effect.Soybean oil control group and Oil-C60Group mouse rises comparatively fast in weight early period, its weight is all higher than during entire medication
The weight of saline control group mouse.Illustrate Oil-C60Apparent toxic side effect is had no to mouse, this also shows Oil-C60
Drug safety.
Claims (10)
1. a kind of application of oil-soluble fullerene structure in the drug that preparation inhibits tumour growth, which is characterized in that the oil
Dissolubility fullerene structure includes at least one of following effective component：It is oil-soluble fullerene, oil soluble metal fullerene, described
The composition of oil-soluble fullerene and the oil soluble metal fullerene, the pharmaceutical ester of the above three or the above three can
Medicinal salt.
2. application according to claim 1, which is characterized in that the oil-soluble fullerene is by fullerene bulk material through oil
It is soluble modified to obtain；The oil soluble metal fullerene is obtained by metal fullerene bulk material through oil-soluble modification.
3. application according to claim 1, which is characterized in that the oil-soluble fullerene is the carbon of fullerene bulk material
Cage outer surface is coated with the modified fullerenes of oil solution, the optional C including edible oil cladding60, edible oil cladding C70Or food
With the C of oil cladding84At least one of；The oil soluble metal fullerene is the carbon cage outer surface of metal fullerene bulk material
It is coated with the modified metal fullerene of oil solution, the optional Gd@C including edible oil cladding82。
4. application according to claim 2 or 3, which is characterized in that the fullerene bulk material includes one or more
General formula is C2mThe cage structure being made of carbon atom, 30≤m≤60, such as；C60, C70, C84Deng.
5. application according to claim 2 or 3, which is characterized in that the metal fullerene bulk material includes M@C2n、
M2@C2n、MA@C2n、M3N@C2n、M2C2@C2n、M2S@C2n、M2O@C2nAnd MxA3-xN@C2nOne of or it is a variety of, wherein：M, A is equal
It represents metallic element and M, A is selected from any one in lanthanide element, Sc and Y, 30≤n≤60；0≤x≤3.
6. application according to claim 2 or 3, which is characterized in that the edible oil can be the oil of one-component, can also
Think the miscella that different oil are formed.Optionally, edible oil is vegetable oil, such as olive oil, linseed oil, sunflower oil, corn
Embryo oil, corn oil, palm oil, at least one of castor oil and soybean oil are also optionally animal fat, such as saualane.
7. application according to claim 2, which is characterized in that the modified method of the oil-soluble includes：With edible oil packet
It covers the fullerene bulk material and/or metal fullerene bulk material obtains the oil-soluble fullerene and/or oil-soluble gold
Belong to fullerene；The mode optionally coated, which can be used, disperses fullerene bulk material and/or metal fullerene bulk material in
In the edible oil, mixed liquor is obtained, by gained mixed liquor successively through centrifugation removal precipitating, is then filtered gained upper liquid,
Up to oil-soluble modification liquid；It is further alternative, it further include the processing of ball milling or ultrasound before the mixed liquor centrifugation.
8. application according to claim 2 or 3, which is characterized in that the oil-soluble fullerene and/or oil soluble metal are rich
It strangles in alkene, the concentration of the fullerene bulk material and/or metal fullerene bulk material can be 50~50000ppm (mg/
Kg), such as 1500ppm.
9. application according to claim 1, which is characterized in that the inhibition tumour growth shows as preventing or slowing down tumour
Growth, optionally include：Inhibit gross tumor volume to increase, the speed that inhibition tumor quality, which increases, slows down gross tumor volume increases, subtract
The speed that slow tumor quality increases.
10. application according to claim 1, which is characterized in that the tumour includes liver cancer, lung cancer, colorectal cancer, kidney
Cancer, cancer of pancreas, osteocarcinoma, breast cancer, oophoroma, prostate cancer, the cancer of the esophagus, gastric cancer, carcinoma of mouth, rhinocarcinoma, laryngocarcinoma, cholangiocarcinoma, palace
At least one of neck cancer, uterine cancer, carcinoma of testis, meningioma, cutaneum carcinoma, melanoma and sarcoma.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710322487.9A CN108853141A (en) | 2017-05-09 | 2017-05-09 | Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation |
| PCT/CN2017/104665 WO2018064963A1 (en) | 2016-10-08 | 2017-09-29 | Use of fullerene structure in preparation of medicament for treating tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710322487.9A CN108853141A (en) | 2017-05-09 | 2017-05-09 | Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108853141A true CN108853141A (en) | 2018-11-23 |
Family
ID=64287384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710322487.9A Pending CN108853141A (en) | 2016-10-08 | 2017-05-09 | Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853141A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111317746A (en) * | 2018-12-13 | 2020-06-23 | 中国科学院化学研究所 | Application of fullerene structure in preparation of drug for treating Alzheimer disease |
| CN115645437A (en) * | 2022-09-26 | 2023-01-31 | 中国科学院化学研究所 | Application of fullerene preparation in preparation of medicine for treating intestinal cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997646A (en) * | 2015-07-09 | 2015-10-28 | 北京福纳康生物技术有限公司 | Oil-soluble fullerene solution and preparation method thereof |
| CN105596368A (en) * | 2016-02-01 | 2016-05-25 | 北京福纳康生物技术有限公司 | Fullerene olive oil composition and application thereof in treatment of Parkinson's disease |
| CN106109494A (en) * | 2016-08-11 | 2016-11-16 | 中国科学院化学研究所 | Prevent and/or treat micro-nano material and the application thereof of bone marrow depression |
-
2017
- 2017-05-09 CN CN201710322487.9A patent/CN108853141A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997646A (en) * | 2015-07-09 | 2015-10-28 | 北京福纳康生物技术有限公司 | Oil-soluble fullerene solution and preparation method thereof |
| CN105596368A (en) * | 2016-02-01 | 2016-05-25 | 北京福纳康生物技术有限公司 | Fullerene olive oil composition and application thereof in treatment of Parkinson's disease |
| CN106109494A (en) * | 2016-08-11 | 2016-11-16 | 中国科学院化学研究所 | Prevent and/or treat micro-nano material and the application thereof of bone marrow depression |
Non-Patent Citations (1)
| Title |
|---|
| 焦芳 等: ""富勒烯化学修饰与生物医学应用研究进展"", 《生态毒理学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111317746A (en) * | 2018-12-13 | 2020-06-23 | 中国科学院化学研究所 | Application of fullerene structure in preparation of drug for treating Alzheimer disease |
| CN115645437A (en) * | 2022-09-26 | 2023-01-31 | 中国科学院化学研究所 | Application of fullerene preparation in preparation of medicine for treating intestinal cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance | |
| CN102056596B (en) | Nanoparticle formulations and uses thereof | |
| CN108743970B (en) | Mitochondrial targeting liposome modified by hyaluronic acid and preparation method thereof | |
| US9005678B1 (en) | Pharmaceutical composition for treating cancer and use thereof | |
| EP1968981B1 (en) | Azaxanthones and use thereof for treating tumors | |
| CN108451930A (en) | Targeting corroles for tumor toxicity and MRI | |
| CN101708337B (en) | Preparation method of human serum albumin nano granules coated with oxaliplatin | |
| CN108853141A (en) | Oil-soluble fullerene structure inhibits the application in tumour growth drug in preparation | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| CN100506962C (en) | Garlic oil refining process and the Preparation process of its emulsion and solid nanometer liposome particle | |
| CN108853142A (en) | Water-soluble fullerene nano particle inhibits the application in tumour growth drug in preparation | |
| CN110585238B (en) | Antitumor drug composition with synergistic effect and application thereof | |
| CN101810577B (en) | Gossypol intravenous injection fatty emulsion for curing tumors | |
| Wang et al. | Multifunctional nano-realgar hydrogel for enhanced glioblastoma synergistic chemotherapy and radiotherapy: a new paradigm of an old drug | |
| JP2011507839A (en) | Drug delivery system for administering water-soluble, cationic and amphiphilic pharmaceutically active substances | |
| CN110623942B (en) | All-trans retinoic acid nano-drug preparation, and preparation method and application thereof | |
| CN109481396A (en) | A kind of fullerene water solution, injection and preparation method thereof | |
| Ao et al. | Sensitive tumor cell line for annonaceous acetogenins and high therapeutic efficacy at a low dose for choriocarcinoma therapy | |
| CN1986543A (en) | Cancer chemotherapy | |
| CN100336552C (en) | Medicine for treating lung cancer | |
| Ranieri et al. | Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel | |
| CN109419773A (en) | Composite Nano lipid drug delivery system and its therapeutic effect to gynecological tumor | |
| CN110448700B (en) | Nano drug-loaded compound for targeted diagnosis and treatment of gastric cancer and preparation method thereof | |
| CN105566147B (en) | A kind of compound and its production and use and corresponding targeting drug delivery system and chemotherapeutics | |
| TWI719182B (en) | Nano-composition, preparation method and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181123 |
|
| RJ01 | Rejection of invention patent application after publication |